For Q1 there were no major events to report and the highlight came in after the quarter ended which was the strategic partnership entered with Curium, global leader in radiopharmaceuticals, for the development and commercialisation of uTRACE for prostate cancer. Curasight is eligible to receive up to USD 70m in development and commercial milestones, as well as double-digit percentage royalties. We reiterate our rNPV-SOTP mid-point value of DKK 54.

Link to the analysis